

20 November 2024

ASX Market Announcements
ASX Limited
Level 4
Stock Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

RESULTS OF ANNUAL GENERAL MEETING

Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri" or the "Company"), hereby provides the results of its annual general meeting of shareholders held on 20 November 2024.

Information required to be disclosed by the Company in accordance with Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act is attached.

All resolutions were passed on a poll. Details of resolutions, the proxies received, and the votes cast on the poll in respect of each resolution are set out in the attached results summary.

For and on behalf of the Board:
Respiri Limited

JUSTIN MOUCHACCA
Company Secretary

-ENDS-

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited – A Revolutionary Remote Healthcare Solutions Provider

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is leading the charge in transforming healthcare delivery in the US. As an innovator in medical devices and MedTech, we combine state-of-the-art technologies with unparalleled clinical expertise. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We're revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.respiri.co/au

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us> or for [wheezo®](#)

Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.

wheezo® is a registered trademark of Respiri Limited

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	347,657,119 97.49%	2,670,447 0.75%	6,272,665 1.76%	489,530	353,929,784 99.25%	2,670,447 0.75%	489,530	Carried
2 Election of Dr Tom Takubo as a Director of the Company	Ordinary	358,397,794 96.69%	1,456,325 0.39%	10,831,352 2.92%	1,677,484	369,229,146 99.61%	1,456,325 0.39%	1,677,484	Carried
3 Re-election of Mr Marjan Mikel as a Director of the Company	Ordinary	359,482,739 96.67%	1,508,288 0.41%	10,851,352 2.92%	520,576	370,334,091 99.59%	1,508,288 0.41%	520,576	Carried
4 Affirmation of Mr Nicholas Smedley as a Director of the Company	Ordinary	358,429,175 96.39%	2,587,060 0.70%	10,831,352 2.91%	515,368	369,260,527 99.30%	2,587,060 0.70%	515,368	Carried
5 Ratification and approval of prior issue of Shares	Ordinary	269,569,336 95.06%	3,177,601 1.12%	10,831,352 3.82%	834,666	280,400,688 98.88%	3,177,601 1.12%	834,666	Carried
6 Ratification and approval of prior issue of Shares	Ordinary	357,373,630 96.20%	3,278,307 0.88%	10,851,352 2.92%	859,666	368,224,982 99.12%	3,278,307 0.88%	859,666	Carried
7 Ratification and approval of prior issue of Shares	Ordinary	217,906,982 93.88%	3,283,307 1.41%	10,935,893 4.71%	839,666	228,842,875 98.59%	3,283,307 1.41%	839,666	Carried
8 Ratification and approval of prior issue of Shares	Ordinary	289,138,240 95.30%	3,278,207 1.08%	10,983,538 3.62%	813,166	300,121,778 98.92%	3,278,207 1.08%	813,166	Carried
9A Ratification and approval of prior issue of Shares	Ordinary	357,358,730 96.19%	3,206,247 0.86%	10,958,312 2.95%	839,666	368,317,042 99.14%	3,206,247 0.86%	839,666	Carried
9B Approval to issue 1,777,778 Shares	Ordinary	333,298,970 97.00%	501,217 0.15%	9,776,426 2.85%	688,166	343,075,396 99.85%	501,217 0.15%	688,166	Carried
10 Appointment of Auditor	Ordinary	358,412,505 96.35%	2,586,360 0.70%	10,971,352 2.95%	392,738	369,383,857 99.30%	2,586,360 0.70%	392,738	Carried
11 Approval of 10% Placement Facility	Special	357,660,693 96.29%	2,899,244 0.78%	10,871,352 2.93%	931,666	368,532,045 99.22%	2,899,244 0.78%	931,666	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.